SCHEMBL135000

SCHEMBL135000

COc1ccc(C(=O)O)cc1S(=O)(=O)Cl

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.71
NPSR1 Q6W5P4 1/20 0.64
CA12 O43570 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA4 P22748 1/20 0.61
CA6 P23280 1/20 0.61
CA7 P43166 1/20 0.61
TPMT P51580 1/20 0.61
CA9 Q16790 1/20 0.61
CA14 Q9ULX7 1/20 0.61
MAPT P10636 1/20 0.58
GAA P10253 1/20 0.58
HTT P42858 2/20 0.56
POLB P06746 2/20 0.56
LMNA P02545 1/20 0.56
MAPK1 P28482 1/20 0.56
RAB9A P51151 1/20 0.56
TDP1 Q9NUW8 1/20 0.53
ALDH1A1 P00352 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28042445 0.87 PKM (0.54) PKMNPSR1CA12CA1CA2
SCHEMBL31172621 0.87 PKM (0.54) PKMNPSR1CA12CA1CA2
SCHEMBL7356053 0.87 CA12 (0.61) PKMNPSR1CA12CA1CA2
SCHEMBL3883855 0.85 PKM (0.56) PKMNPSR1CA12CA1CA2
SCHEMBL1020735 0.85 MAPT (0.55) PKMNPSR1CA12CA1CA2
SCHEMBL29430636 0.85 MAPT (0.55) PKMNPSR1CA12CA1CA2
SCHEMBL2565798 0.85 PKM (0.73) PKMNPSR1CA12CA1CA2
SCHEMBL2592861 0.83 PKM (1.00) PKMNPSR1CA12CA1CA2
SCHEMBL3973973 0.81 NPSR1 (0.74) PKMNPSR1CA12CA1CA2
SCHEMBL7621544 0.80 HSD17B2 (0.58) PKMCA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180153787-A1 METHODS AND ARTICLES OF MANUFACTURE FOR THE TREATMENT OF SKIN Advanced Collagen Science LLC 2018-06-07 US claimed
US-20160038391-A1 METHODS AND ARTICLES OF MANUFACTURE FOR THE TREATMENT OF SKIN Advanced Collagen Science LLC (US) 2016-02-11 US claimed
EP-2981324-A2 METHODS AND ARTICLES OF MANUFACTURE FOR THE TREATMENT OF SKIN Miller, Leonard B. (US) 2016-02-10 EP claimed
WO-2014165741-A2 METHODS AND ARTICLES OF MANUFACTURE FOR THE TREATMENT OF SKIN MILLER LEONARD B (US) 2014-10-09 WO claimed
US-12485169-B2 Compounds Grey Wolf Therapeutics Limited (GB) 2025-12-02 US disclosed
CN-120025279-A Compounds capable of modulating endoplasmic reticulum aminopeptidase 1 格雷沃尔夫治疗有限公司 2025-05-23 CN disclosed
WO-2025036382-A1 SULFONAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海复宏汉霖生物医药有限公司 2025-02-20 WO disclosed
US-20240189188-A1 DEVICES AND METHODS FOR CORNEA TREATMENT D&D Biopharmaceuticals, Inc. (US) 2024-06-13 US disclosed
WO-2024118773-A1 DEVICES AND METHODS FOR CORNEA TREATMENT D&D Biopharmaceuticals, Inc. (US) 2024-06-06 WO disclosed
US-11938092-B1 Devices and methods for cornea treatment D&D Biopharmaceuticals, Inc. (US) 2024-03-26 US disclosed
US-20230064417-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2023-03-02 US disclosed
WO-2023007188-A1 PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS Grey Wolf Therapeutics Limited (GB) 2023-02-02 WO disclosed
US-6096768-A ADMINISTERING A 3, 5, 6-SUBSTITUTED PHENYL COMPOUND FOR THE TREATMENT OF INFLAMMATION AND AUTOIMMUNE DISORDERS RHONE-POULENC RORER LIMITED (GB) 2000-08-01 US disclosed
WO-2000017192-A1 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE MERCKLE GMBH (DE) 2000-03-30 WO disclosed
US-5935978-A Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group RHONE-POULENC RORER LIMITED (GB) 1999-08-10 US disclosed
US-5840724-A COMPOUNDS FOR TUMOR NECROSIS FACTOR OR ENZYME INHIBITORS OF PHOSPHODIESTERASES RHONE-POULENC RORER LIMITED (GB) 1998-11-24 US disclosed
US-5698711-A INHIBITORS OF TUMOR NECROSIS FACTOR, CYCLIC ADENOSINE-3*,5*-MONOPHOSPHATE PHOSPHODIESTERASE AND EOSINOPHILS RHONE-POULENC RORER LIMITED (GB) 1997-12-16 US disclosed
US-5679696-A FOR INHIBITING TUMOR NECROSIS FACTOR; ENZYME INHIBITORS RHONE-POULENC RORER LIMITED (GB) 1997-10-21 US disclosed
EP-0652868-A1 INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF RHONE-POULENC RORER LIMITED (GB) 1995-05-17 EP disclosed
WO-1994002465-A1 INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF RHONE-POULENC RORER LIMITED (GB) 1994-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230064417-A1 COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 PKM 4215/4885NPSR1 80/4885CA12 194/4885
US-12485169-B2 Compounds SLC10A1, VHL, CFTR PKM 1612/4885NPSR1 1166/4885CA12 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.